Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALGS

Aligos Therapeutics Inc

Dec 13 • 04:00PM ET

34.07

Dollar change +0.96
Percentage change 2.90	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX GILD ARWR RAPT NBIX ABUS AKRO BCRX AMLX ALT

| Held by: VTI SCHA VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.35	Insider Own	25.51%	Shs Outstand	3.20M	Perf Week	18.84%
Market Cap	125.78M	Forward P/E	-	EPS next Y	-11.92	Insider Trans	0.00%	Shs Float	2.67M	Perf Month	74.00%
Income	-76.95M	PEG	-	EPS next Q	-2.50	Inst Own	43.20%	Short Float	10.63%	Perf Quarter	139.59%
Sales	6.00M	P/S	20.96	EPS this Y	70.31%	Inst Trans	-19.56%	Short Ratio	0.88	Perf Half Y	172.56%
Book/sh	15.07	P/B	2.26	EPS next Y	-18.06%	ROA	-88.31%	Short Interest	0.28M	Perf Year	132.96%
Cash/sh	20.32	P/C	1.68	EPS next 5Y	-	ROE	-146.69%	52W Range	6.76 - 35.30	Perf YTD	105.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-137.84%	52W High	-3.48%	Beta	2.70
Dividend TTM	-	Quick Ratio	3.81	Sales past 5Y	46.14%	Gross Margin	54.54%	52W Low	403.99%	ATR (14)	2.97
Dividend Ex-Date	-	Current Ratio	3.81	EPS Y/Y TTM	-	Oper. Margin	-1577.26%	RSI (14)	79.96	Volatility	12.84% 15.95%
Employees	66	Debt/Eq	0.18	Sales Y/Y TTM	-63.40%	Profit Margin	-1283.19%	Recom	1.00	Target Price	103.33
Option/Short	No / Yes	LT Debt/Eq	0.11	EPS Q/Q	-	Payout	-	Rel Volume	0.98	Prev Close	33.11
Sales Surprise	280.74%	EPS Surprise	-42.35%	Sales Q/Q	-60.82%	Earnings	Nov 06 AMC	Avg Volume	323.46K	Price	34.07
SMA20	35.98%	SMA50	115.92%	SMA200	113.51%	Trades		Volume	315,881	Change	2.90%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-24	Initiated	H.C. Wainwright	Buy	$75
Jan-06-23	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $3
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$2.50 → $3
Mar-23-22	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $4
Jan-07-22	Downgrade	JP Morgan	Overweight → Neutral	$30 → $12
Jan-06-22	Downgrade	Jefferies	Buy → Hold
Sep-09-21	Initiated	SVB Leerink	Outperform	$29
May-17-21	Resumed	Piper Sandler	Overweight	$47
Nov-10-20	Initiated	Piper Sandler	Overweight	$35
Nov-10-20	Initiated	JP Morgan	Overweight	$33
Nov-10-20	Initiated	Jefferies	Buy	$26
Nov-10-20	Initiated	Cantor Fitzgerald	Overweight	$28

Show Previous Ratings

Dec-13-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 08:00AM	Aligos Therapeutics to Present at Investor Conferences in December (GlobeNewswire)
Nov-19-24 01:30PM	Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 (GlobeNewswire) -8.05%
Nov-06-24 06:05PM	Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +6.10%
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results (GlobeNewswire)
04:05PM	Loading…
Oct-30-24 04:05PM	Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-22-24 08:00AM	Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 (GlobeNewswire)
Oct-15-24 09:00AM	Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024 (GlobeNewswire)
Oct-11-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.60%
Oct-01-24 08:00AM	Aligos Therapeutics Appoints David Perry as Vice President of Business Development (GlobeNewswire)
Sep-30-24 08:00AM	Aligos Therapeutics to Present at Investor Conferences in October (GlobeNewswire) +7.71%
Sep-24-24 08:00AM	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer (GlobeNewswire)
Sep-20-24 04:52AM	Aligos reports positive data from Phase IIa MASH treatment trial (Clinical Trials Arena) -10.22%
Sep-19-24 08:00AM	Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH (GlobeNewswire) -28.11%
Sep-18-24 05:00PM	Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 (GlobeNewswire)
08:00AM	Loading…
Sep-13-24 08:00AM	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.49%
Sep-10-24 09:40AM	Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? (Zacks) -29.03%
Aug-21-24 09:55AM	How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% (Zacks) -5.04%
Aug-15-24 09:00AM	Aligos Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Aug-09-24 12:00PM	What Makes Aligos Therapeutics (ALGS) a New Buy Stock (Zacks)
Aug-08-24 04:05PM	Aligos Therapeutics Strengthens Board with Two New Independent Directors (GlobeNewswire)
Aug-07-24 12:53PM	Hepatitis B market is ripe for treatment development, says Aligos CEO (Pharmaceutical Technology) +21.95%
Aug-06-24 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 04:05PM	Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-22-24 09:00AM	Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. (GlobeNewswire) +11.08%
Jul-10-24 08:00AM	Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB (GlobeNewswire) +7.89%
Jun-05-24 02:30AM	Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 (GlobeNewswire)
Jun-04-24 09:55AM	Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now (Zacks)
May-22-24 04:05PM	Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 (GlobeNewswire) -8.95%
May-21-24 08:00AM	Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH (GlobeNewswire)
09:35AM	Loading…
May-16-24 09:35AM	After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS) (Zacks)
May-07-24 09:56PM	ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 04:05PM	Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-25-24 04:05PM	Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study (GlobeNewswire)
08:00AM	Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD (GlobeNewswire)
Apr-09-24 08:00AM	Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects (GlobeNewswire)
Mar-27-24 09:55AM	Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
08:00AM	Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies (GlobeNewswire)
Mar-18-24 08:00AM	Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects (GlobeNewswire)
Mar-12-24 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:05PM	Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Feb-26-24 08:00AM	Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire) +21.33%
Feb-20-24 08:00AM	Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024 (GlobeNewswire)
Feb-13-24 08:00AM	Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments (GlobeNewswire) -6.18%
Jan-05-24 09:40AM	Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-07-23 04:05PM	Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) (GlobeNewswire) -10.77%
Nov-24-23 10:26AM	13 Stocks Insiders are Buying Now (Insider Monkey) +5.29%
Nov-20-23 04:05PM	Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference (GlobeNewswire) -9.17%
09:10AM	Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today? (InvestorPlace)
Nov-13-23 08:00AM	Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile (GlobeNewswire) -14.13%
Nov-10-23 08:05AM	Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg) (GlobeNewswire) -9.26%
Nov-07-23 08:00AM	Aligos Therapeutics to Present Multiple Posters at AASLD's The Liver Meeting 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR- Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company's Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C) (GlobeNewswire)
Nov-03-23 04:30PM	Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data (GlobeNewswire)
Nov-02-23 06:57PM	Aligos Therapeutics Inc (ALGS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-30-23 01:06PM	Hedge Fund and Insider Trading News: Joseph Edelman, Ken Griffin, Seth Klarman, Two Sigma Advisors, Sculptor Capital Management, Aligos Therapeutics Inc (ALGS), The Progressive Corporation (PGR), and More (Insider Monkey)
Oct-26-23 04:05PM	Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023 (GlobeNewswire)
Oct-25-23 08:00AM	Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting 2023 (GlobeNewswire)
Oct-23-23 08:00AM	Aligos Therapeutics Announces $92 Million Private Placement Financing (GlobeNewswire) -21.52%
Oct-03-23 07:30AM	Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558 (GlobeNewswire)
Sep-21-23 07:30AM	Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009 (GlobeNewswire)
Aug-03-23 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-27-23 04:05PM	Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023 (GlobeNewswire)
Jul-19-23 07:30AM	Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009 (GlobeNewswire)
Jun-21-23 04:30PM	Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Jun-07-23 07:30AM	Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Jun-05-23 06:09AM	We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-24-23 05:26PM	Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-12-23 05:05PM	Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos Oligonucleotide Platform for the Treatment of Liver Diseases (GlobeNewswire) +19.27%
May-04-23 07:25PM	Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.82%
04:05PM	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:05PM	Aligos Therapeutics to Announce First Quarter Results on May 4, 2023 (GlobeNewswire) +8.41%
Apr-17-23 06:51AM	Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 30% Dip In Price Shows Sentiment Is Matching Revenues (Simply Wall St.)
Apr-11-23 06:50PM	Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
Mar-29-23 04:05PM	Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference (GlobeNewswire) -6.73%
Mar-09-23 06:25PM	Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.21%
04:05PM	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:05PM	Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023 (GlobeNewswire) -7.01%
Feb-16-23 08:00AM	Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (GlobeNewswire)
Feb-14-23 08:00AM	Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (GlobeNewswire) +7.24%
Feb-10-23 07:00AM	Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire) -11.11%
Feb-09-23 11:39AM	Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce (Benzinga) -8.06%
Feb-08-23 04:05PM	Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024 (GlobeNewswire)
Jan-23-23 07:53AM	Aligos Therapeutics (NASDAQ:ALGS) adds US$18m to market cap in the past 7 days, though investors from a year ago are still down 34% (Simply Wall St.) -6.31%
Jan-05-23 08:00AM	Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009 (GlobeNewswire) +5.32%
Dec-14-22 04:05PM	Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB) (GlobeNewswire) -5.00%
Dec-08-22 08:00AM	Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting (GlobeNewswire)
Dec-05-22 05:13AM	We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Nov-04-22 08:05AM	Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLDs The Liver Meeting® 2022 (GlobeNewswire) -5.71%
08:00AM	Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLDs The Liver Meeting® 2022 (GlobeNewswire)
Nov-02-22 04:05PM	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-21-22 09:05AM	Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLDs The Liver Meeting® 2022 (GlobeNewswire)
Oct-19-22 04:15PM	Aligos Therapeutics to Announce Third Quarter Results November 2, 2022 (GlobeNewswire)
Oct-18-22 07:30AM	Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institutes 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA (GlobeNewswire)
Oct-14-22 08:00AM	Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755 (GlobeNewswire)
Sep-29-22 08:40AM	Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud (Benzinga)
Sep-28-22 04:32PM	Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud (GlobeNewswire)
Aug-16-22 08:00AM	The past year for Aligos Therapeutics (NASDAQ:ALGS) investors has not been profitable (Simply Wall St.) -5.13%

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALGS

Aligos Therapeutics Inc

Upgrade your FINVIZ experience